{"id":"cytarabine-ocfosfate","rwe":[{"pmid":"37670479","year":"2023","title":"Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs.","finding":"","journal":"Journal of veterinary internal medicine","studyType":"Clinical Study"},{"pmid":"25652695","year":"2015","title":"Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate.","finding":"","journal":"Journal of hematology & oncology","studyType":"Clinical Study"},{"pmid":"24080768","year":"2013","title":"Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients.","finding":"","journal":"Chemotherapy","studyType":"Clinical Study"},{"pmid":"18228114","year":"2008","title":"The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients.","finding":"","journal":"International journal of hematology","studyType":"Clinical Study"},{"pmid":"15550587","year":"2004","title":"Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.","finding":"","journal":"Annals of oncology : official journal of the European Society for Medical Oncology","studyType":"Clinical Study"}],"tags":[{"label":"Nucleoside Metabolic Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Antimetabolites, Antineoplastic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"},{"label":"Immunosuppressive Agents","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":["NCT04425655","NCT01297543","NCT04415008","NCT01941680","NCT00053105","NCT05444712","NCT00991744","NCT02583893","NCT07244367","NCT05372536","NCT02385955","NCT00995332","NCT00932412","NCT00866307","NCT01296178","NCT01193400","NCT02310321","NCT06429098","NCT06561152","NCT01488344","NCT07319793","NCT04659616","NCT02957032","NCT00084838","NCT03634228","NCT01382147","NCT00632749","NCT00004643","NCT01828489","NCT00064090","NCT06210750","NCT04931368","NCT02056782","NCT01795924","NCT07175415","NCT00367497","NCT00534469","NCT04982354","NCT00655395","NCT00180167","NCT00822094","NCT00274807","NCT00137995","NCT01534702","NCT04047628","NCT06190457","NCT01665001","NCT00074737","NCT02443077","NCT04891757"],"aliases":[],"patents":[],"pricing":[],"allNames":"starasid","offLabel":[],"synonyms":["cytarabine ocfosate","fosteabine","cytarabine ocfosfate","cytarabine ocfosphate hydrate","fosteabine sodium monohydrate","starasid"],"timeline":[],"approvals":[],"brandName":"Starasid","ecosystem":[],"mechanism":{"moaClass":"Nucleic Acid Synthesis Inhibitors","modality":"Small Molecule","drugClass":"Nucleoside Metabolic Inhibitor","explanation":"Imagine DNA as a blueprint for a house. Starasid is like a tool that prevents the blueprint from being copied, so the house can't be built. This stops the cancer cells from growing and dividing, which can help slow down or even stop the growth of the tumor.","oneSentence":"Starasid works by interfering with the replication of DNA in cancer cells, preventing them from growing and dividing.","technicalDetail":"Cytarabine ocfosfate is a prodrug that is converted into its active form, cytarabine, which is then incorporated into DNA, causing chain termination and inhibiting DNA synthesis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/771","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cytarabine ocfosfate","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:26:32.911362","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"cytarabine ocfosfate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04425655","phase":"Phase 2","title":"A Phase II Trial of Fludarabine in Combination With Daunorubicin and Cytarabine Liposome for Adults With Newly-diagnosed Acute Myeloid Leukemia: University of California Hematologic Malignancies Conso","status":"TERMINATED","sponsor":"University of California, San Diego","isPivotal":false,"enrollment":2,"indication":"Acute Myeloid Leukemia, Adult, AML","completionDate":"2022-07-01"},{"nctId":"NCT01297543","phase":"Phase 1","title":"A Phase I/II Trial of CLT-008 Myeloid Progenitor Cells in Patients Receiving Chemotherapy for Leukemia or Myelodysplasia","status":"COMPLETED","sponsor":"Cellerant Therapeutics","isPivotal":false,"enrollment":45,"indication":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia","completionDate":"2015-01"},{"nctId":"NCT04415008","phase":"Phase 2","title":"A Prospective, Multicenter, Single Arm Clinical Study to Evaluate Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","isPivotal":false,"enrollment":61,"indication":"CEBPA Double Mutation, Acute Myeloid Leukemia","completionDate":"2027-06-01"},{"nctId":"NCT01941680","phase":"N/A","title":"Observational Prospective Study, Evaluating the Standard of Care as Recommend by International Consensus With Zidovudine-Pegylated Interferon +/-Polychemotherapy in High Risk Adult-T-cell Lymphoma/Leu","status":"COMPLETED","sponsor":"University Hospital Center of Martinique","isPivotal":false,"enrollment":20,"indication":"T-cell Lymphoma, Leukaemia","completionDate":"2021-03"},{"nctId":"NCT00053105","phase":"Phase 1","title":"A Phase I Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Theradex","isPivotal":false,"enrollment":0,"indication":"Lymphoma","completionDate":""},{"nctId":"NCT05444712","phase":"NA","title":"Transplantation After Complete Response In Patients With T-cell Lymphoma","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","isPivotal":false,"enrollment":204,"indication":"Peripheral T Cell Lymphoma","completionDate":"2028-04-01"},{"nctId":"NCT00991744","phase":"Phase 3","title":"Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 ","status":"SUSPENDED","sponsor":"Nordic Society for Pediatric Hematology and Oncology","isPivotal":true,"enrollment":100,"indication":"Acute Lymphoblastic Leukemia","completionDate":"2018-12"},{"nctId":"NCT02583893","phase":"Phase 2","title":"A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","isPivotal":false,"enrollment":39,"indication":"Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia","completionDate":"2023-05-17"},{"nctId":"NCT07244367","phase":"NA","title":"Maintenance Venetoclax Based Therapy Post Complete Remission in AML Fit Patients","status":"RECRUITING","sponsor":"Sohag University","isPivotal":false,"enrollment":80,"indication":"Acute Myeloid Leukaemia (AML)","completionDate":"2027-09-01"},{"nctId":"NCT05372536","phase":"NA","title":"Parent-Administered Low-Dose Cytarabine to Children and Adolescents With Cancer at Home - a Feasibility Study","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","isPivotal":false,"enrollment":15,"indication":"Supportive Care, Childhood Cancer","completionDate":"2023-04-01"},{"nctId":"NCT02385955","phase":"Phase 2","title":"Prospective Multicenter Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients With Hematologic Malignancies","status":"UNKNOWN","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":39,"indication":"Hematologic Malignancy","completionDate":"2019-04"},{"nctId":"NCT00995332","phase":"Phase 1","title":"Treatment of Acute Myelogenous Leukemia With the Histone Deacetylase Inhibitor Valproic Cid in Combination With All-trans Retinoic Acid (ATRA) and Low Dose Cytarabine","status":"COMPLETED","sponsor":"University of Bergen","isPivotal":false,"enrollment":36,"indication":"Acute Myelogenous Leukemia","completionDate":"2013-06"},{"nctId":"NCT00932412","phase":"Phase 2","title":"A Randomized Phase II Study of Clofarabine / Intermediate-Dose Cytarabine (CLARA)Versus High-Dose Cytarabine (HDAC) as Consolidation in Younger Patients With Newly-Diagnosed Acute Myeloid Leukemia (AM","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","isPivotal":false,"enrollment":735,"indication":"Acute Myeloid Leukemia","completionDate":"2016-04"},{"nctId":"NCT00866307","phase":"Phase 1","title":"Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study","status":"COMPLETED","sponsor":"Children's Oncology Group","isPivotal":false,"enrollment":104,"indication":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia","completionDate":"2021-03-31"},{"nctId":"NCT01296178","phase":"NA","title":"PROTOCOL FOR First Line TREATMENT ADAPTED TO RISK of Acute Myeloblastic Leukemia in Patients LESS THAN OR EQUAL TO 65 YEARS","status":"UNKNOWN","sponsor":"PETHEMA Foundation","isPivotal":false,"enrollment":200,"indication":"Acute Myeloblastic Leukemia","completionDate":"2021-12"},{"nctId":"NCT01193400","phase":"Phase 2","title":"Multicentric Phase II Trial, Prospective, Open, Single Group, to Discuss Induction Therapy With a Combination of Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy With Clofarabine ","status":"TERMINATED","sponsor":"PETHEMA Foundation","isPivotal":false,"enrollment":75,"indication":"Acute Myelogenous Leukemia","completionDate":"2012-02"},{"nctId":"NCT02310321","phase":"Phase 1","title":"A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","isPivotal":false,"enrollment":97,"indication":"Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia","completionDate":"2024-07-09"},{"nctId":"NCT06429098","phase":"Phase 2","title":"Study of A Venetoclax-based, Anthracycline-free Regimen in Patients With Newly Diagnosed CBFβ::MYH11-positive Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","isPivotal":false,"enrollment":40,"indication":"Acute Myeloid Leukemia","completionDate":"2027-12-31"},{"nctId":"NCT06561152","phase":"Phase 1","title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123-Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Stanford University","isPivotal":false,"enrollment":20,"indication":"Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia","completionDate":"2028-10"},{"nctId":"NCT01488344","phase":"Phase 1","title":"A Single-arm, Open Label, Multi-center Phase I/II Trial to Assess the Safety and Efficacy of BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML Unfit for an Intensive Induction Therap","status":"UNKNOWN","sponsor":"University Hospital Muenster","isPivotal":false,"enrollment":140,"indication":"Acute Myeloid Leukemia","completionDate":""},{"nctId":"NCT07319793","phase":"NA","title":"Clinical Study on Optimized Treatment for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Myeloid Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","isPivotal":false,"enrollment":200,"indication":"Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS)","completionDate":"2028-06-30"},{"nctId":"NCT04659616","phase":"Phase 1","title":"A Multicenter, Phase 1, Open-Label Study of the FGFR Inhibitor Pemigatinib (INCB054828) Administered After Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With Adverse or Intermediate Ris","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","isPivotal":false,"enrollment":32,"indication":"Acute Myeloid Leukemia","completionDate":"2026-12-31"},{"nctId":"NCT02957032","phase":"Phase 1","title":"A Dose-finding Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic ","status":"TERMINATED","sponsor":"Philogen S.p.A.","isPivotal":false,"enrollment":30,"indication":"Acute Myeloid Leukemia, Relapsed, Adult","completionDate":"2023-09-29"},{"nctId":"NCT00084838","phase":"Phase 2","title":"A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","isPivotal":false,"enrollment":25,"indication":"Central Nervous System Tumor, Pediatric","completionDate":"2013-03"},{"nctId":"NCT03634228","phase":"Phase 1","title":"A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b (Milademetan) in Combination With Low Dose Cytarabine (LDAC) in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":16,"indication":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia","completionDate":"2022-04-03"},{"nctId":"NCT01382147","phase":"Phase 3","title":"A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (Sequential High Dose Cytosine Arabinoside and Mitoxantrone) Versus Standard Double Induction for Initial Chemotherapy of ","status":"COMPLETED","sponsor":"Prof. Dr. Wolfgang Hiddemann","isPivotal":true,"enrollment":396,"indication":"Acute Myeloid Leukemia","completionDate":"2017-07-05"},{"nctId":"NCT00632749","phase":"Phase 2","title":"An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Efficacy and Pharmacokinetics of BI 811283 in Combination With Cytarabine in Patients With Previously Untreated Acute Myelo","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":68,"indication":"Leukemia, Myeloid, Acute","completionDate":"2014-03"},{"nctId":"NCT00004643","phase":"Phase 2","title":"","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","isPivotal":false,"enrollment":10,"indication":"Lupus Erythematosus, Systemic","completionDate":""},{"nctId":"NCT01828489","phase":"Phase 3","title":"NOPHO-DBH AML 2012 Protocol. Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","isPivotal":true,"enrollment":300,"indication":"Pediatric Acute Myeloblastic Leukemia","completionDate":"2023-03"},{"nctId":"NCT00064090","phase":"Phase 1","title":"A Phase I Study of Triapine and Cytarabine in Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Vion Pharmaceuticals","isPivotal":false,"enrollment":0,"indication":"Leukemia, Myelodysplastic Syndromes","completionDate":"2008-01"},{"nctId":"NCT06210750","phase":"Phase 2","title":"A Randomized Phase 2 Trial to Evaluate the Efficacy of BCL-2 Inhibitor Therapy With Chemotherapy Compared to Chemotherapy Alone in Adult Patients With Newly Diagnosed T-Cell ALL and T-Cell Lymphoblast","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":0,"indication":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","completionDate":"2026-09-22"},{"nctId":"NCT04931368","phase":"Phase 3","title":"Optimizing MATRix as Remission Induction in PCNSL: De-escalated Induction Treatment in Newly Diagnosed Primary CNS Lymphoma - a Randomized Phase III Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Klinikum Stuttgart","isPivotal":true,"enrollment":331,"indication":"Primary Central Nervous System Lymphoma","completionDate":"2028-11"},{"nctId":"NCT02056782","phase":"Phase 1","title":"A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Ther","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","isPivotal":false,"enrollment":12,"indication":"Acute Myeloid Leukemia","completionDate":"2015-06"},{"nctId":"NCT01795924","phase":"Phase 1","title":"An Open-Label, Phase 1/2 Study of PD-616 and Low-dose Cytarabine in Patients With Untreated or Relapsed/Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Biosuccess Biotech Co., Ltd.","isPivotal":false,"enrollment":13,"indication":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome","completionDate":"2014-11"},{"nctId":"NCT07175415","phase":"Phase 1","title":"ITCC-104: HEM-iSMART International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Sub-Protocol E: Capivasert","status":"NOT_YET_RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","isPivotal":false,"enrollment":42,"indication":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent","completionDate":"2032-10-01"},{"nctId":"NCT00367497","phase":"Phase 2","title":"Phase 2 Study of Rituximab and ESHAP (Etoposide, Methylprednisolone, Cytarabine, and Cisplatin) in Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Keio University","isPivotal":false,"enrollment":5,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2007-11"},{"nctId":"NCT00534469","phase":"Phase 2","title":"Autologous Bone Marrow Transplantation for Non-M3 Acute Myeloid Leukemia (AML) in First Remission in Patients </=60 Years of Age Using Busulfan/Fractionated Total Body Irradiation (FTBI) and VP16 as t","status":"COMPLETED","sponsor":"City of Hope Medical Center","isPivotal":false,"enrollment":60,"indication":"Leukemia","completionDate":"2025-07-16"},{"nctId":"NCT04982354","phase":"Phase 1","title":"A Pilot Study of Daunorubicin-cytarabine Liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) as Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Followed by Consolidation With ","status":"WITHDRAWN","sponsor":"Guenther Koehne","isPivotal":false,"enrollment":0,"indication":"Acute Myeloid Leukemia","completionDate":"2032-08-01"},{"nctId":"NCT00655395","phase":"Phase 1","title":"A Phase I/Phase II Evaluation of Laromustine (VNP40101M), A Sulfonylhydrazine Alkylating Agent, Combined With Infusional Cytarabine in Elderly Patients With Acute Myeloid Leukemia and High Risk Myelod","status":"TERMINATED","sponsor":"Viron Therapeutics Inc","isPivotal":false,"enrollment":25,"indication":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)","completionDate":"2010-10"},{"nctId":"NCT00180167","phase":"Phase 4","title":"Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermitte","status":"COMPLETED","sponsor":"Technische Universität Dresden","isPivotal":false,"enrollment":492,"indication":"Leukemia, Nonlymphocytic, Acute","completionDate":"2010-07"},{"nctId":"NCT00822094","phase":"Phase 2","title":"Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relap","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","isPivotal":false,"enrollment":126,"indication":"Acute Myeloid Leukemia","completionDate":"2012-01"},{"nctId":"NCT00274807","phase":"Phase 2","title":"Intensive Induction for Newly Diagnosed Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"The Cleveland Clinic","isPivotal":false,"enrollment":40,"indication":"Leukemia","completionDate":"2008-05"},{"nctId":"NCT00137995","phase":"Phase 3","title":"Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab","status":"COMPLETED","sponsor":"Lymphoma Study Association","isPivotal":true,"enrollment":481,"indication":"Lymphoma, Large-Cell, Diffuse","completionDate":"2008-10"},{"nctId":"NCT01534702","phase":"Phase 1","title":"Phase I/II Study on Cytarabine and Idarubicin Combined With Escalating Doses of Clofarabine as Induction Therapy in Patients With Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-1","status":"UNKNOWN","sponsor":"Hannover Medical School","isPivotal":false,"enrollment":60,"indication":"Acute Myeloid Leukemia","completionDate":"2015-09"},{"nctId":"NCT04047628","phase":"Phase 3","title":"A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":true,"enrollment":156,"indication":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis","completionDate":"2029-10"},{"nctId":"NCT06190457","phase":"N/A","title":"Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","isPivotal":false,"enrollment":16,"indication":"Lymphoma, Non-Hodgkin, Child, Only","completionDate":"2022-08-30"},{"nctId":"NCT01665001","phase":"Phase 2","title":"Optimization of the Treatment of Adults With Precursor Lymphoid Neoplasms With Adjustment of the Type and Intensity of the Therapy for Age, Status of Minimal Residual Disease, Genetic and Phenotypic F","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice","isPivotal":false,"enrollment":200,"indication":"Precursor Lymphoid Neoplasms","completionDate":"2018-08"},{"nctId":"NCT00074737","phase":"Phase 2","title":"Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination With EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia (AML)","status":"COMPLETED","sponsor":"Eleos, Inc.","isPivotal":false,"enrollment":53,"indication":"Acute Myelogenous Leukemia","completionDate":"2007-05"},{"nctId":"NCT02443077","phase":"Phase 3","title":"A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","isPivotal":true,"enrollment":94,"indication":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","completionDate":"2026-12-23"},{"nctId":"NCT04891757","phase":"Phase 1","title":"A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy o","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foghorn Therapeutics Inc.","isPivotal":false,"enrollment":144,"indication":"Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia","completionDate":"2027-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"MMSL":"372","NDDF":"002649","UNII":"3I7U8R8NWC","CHEBI":"CHEBI:135838","VANDF":"4018080","INN_ID":"1709","RXNORM":"3041","UMLSCUI":"C0089089","DRUGBANK_ID":"DB00987","PDB_CHEM_ID":" AR3","PUBCHEM_CID":"6918130","SNOMEDCT_US":"387511003","SECONDARY_CAS_RN":"65093-40-5","MESH_DESCRIPTOR_UI":"D003561","MESH_SUPPLEMENTAL_RECORD_UI":"C061162"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":44,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2023 Nov-Dec","pmid":"37670479","title":"Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs.","journal":"Journal of veterinary internal medicine"},{"date":"2015 Feb 6","pmid":"25652695","title":"Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate.","journal":"Journal of hematology & oncology"},{"date":"2013","pmid":"24080768","title":"Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients.","journal":"Chemotherapy"},{"date":"2008 Mar","pmid":"18228114","title":"The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients.","journal":"International journal of hematology"},{"date":"2004 Dec","pmid":"15550587","title":"Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.","journal":"Annals of oncology : official journal of the European Society for Medical Oncology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Starasid (cytarabine ocfosfate) is a nucleoside metabolic inhibitor, a small molecule drug that targets cancer cells. It is used to treat certain types of cancer, but its exact target is unknown. The commercial status of Starasid is unclear, and it may be patented or have generic manufacturers. Key safety considerations include potential side effects, but specific details are not available. Further research is needed to fully understand the drug's properties and uses.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}